Tempus AI, Inc. (NASDAQ:TEM) announced on Monday a definitive agreement to acquire Personalis, Inc. (NASDAQ:PSNL), aiming to advance cancer monitoring through enhanced minimal residual disease (MRD) capabilities.

This acquisition, valued at $1.5 billion, is set to expand Tempus’ reach in the MRD market. Tempus claims it presents a $20 billion opportunity.

Key Deal Terms

  • Transaction Value: $1.5 billion enterprise value, net of Tempus’ existing ownership interest.
  • Shareholder Consideration: Personalis shareholders to receive $16.25 per share.
  • Preliminary Revenue: Personalis reported Q2 revenue of $22.4 million with a 33% increase in test volumes.
  • Market Opportunity: The MRD market is estimated at $20 billion.
  • Exchange Ratio: Max exchange ratio of 0.3356 for Tempus AI common stock.

Strategic Rationale

According to Eric Lefkofsky, CEO of Tempus, the acquisition will leverage Personalis’ MRD technology with Tempus’ AI and data platform to improve cancer patient monitoring and treatment.

"Through our existing collaboration with Personalis, we have already demonstrated the strength of combining highly sensitive MRD technology with our commercial infrastructure. With clinical adoption and reimbursement momentum building, we are collectively well positioned to capture this opportunity, which makes this acquisition particularly exciting."

Chris Hall, CEO of Personalis, expressed confidence in the deal, highlighting the combined capabilities and resources that will accelerate innovation and deliver value to patients and shareholders.

The acquisition builds on an existing partnership between Tempus and Personalis, which began in November 2023. This collaboration had already demonstrated the efficacy of combining MRD technology with Tempus’ infrastructure.

Structure And Closing

Tempus will primarily pay for the transaction with stock but may use cash for up to 50% of the consideration.

The $16.25-per-share offer represents a 6% premium to Personalis’ Friday closing price. It also carries a 28% premium to the unaffected 30-day volume-weighted average price.

The acquisition is expected to close in late 2026 or early 2027.

Tempus AI held $521.17 million in cash and cash equivalents as of March 31, 2026.

Tempus AI Earnings Preview

Tempus will report earnings on July 30, 2026.

Analysts expect the company to post a loss of 20 cents per share, narrowing from 22 cents a year earlier. They forecast revenue of $380.24 million, up from $314.63 million.

Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price forecast of $66.82. Recent analyst moves include:

  • Guggenheim: Buy (Raises Target to $65.00) (July 16)
  • Freedom Capital Markets: Initiated with Hold (Target $59.00) (July 1)
  • Needham: Buy (Maintains Target to $75.00) (June 1)

TEM Price Action: Tempus AI shares were down 8.06% at $48.24 at the time of publication on Monday, according to Benzinga Pro data.

Read Also: Anthropic Is Going All In on Drug Discovery Just as Pharma Stops Talking About AI

Photo: Shutterstock